NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $0 | – | 10 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 10 | -97.6% | 0.00% | -100.0% |
| Q2 2021 | $7,000 | -12.5% | 410 | -0.7% | 0.00% | 0.0% |
| Q1 2021 | $8,000 | – | 413 | +3076.9% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 13 | -99.8% | 0.00% | -100.0% |
| Q3 2020 | $94,000 | -7.8% | 5,695 | -0.2% | 0.01% | -23.1% |
| Q1 2020 | $102,000 | -22.1% | 5,708 | -5.8% | 0.01% | -7.1% |
| Q4 2019 | $131,000 | +84.5% | 6,058 | +55.6% | 0.01% | +75.0% |
| Q3 2019 | $71,000 | -48.2% | 3,894 | +1.1% | 0.01% | -46.7% |
| Q2 2019 | $137,000 | +3325.0% | 3,851 | +3219.8% | 0.02% | +1400.0% |
| Q4 2018 | $4,000 | -99.9% | 116 | -57.8% | 0.00% | 0.0% |
| Q2 2017 | $5,000,000 | 0.0% | 275 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $5,000,000 | – | 275 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |